Mineralys Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Mineralys Therapeutics has a total shareholder equity of $328.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $347.2M and $19.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$338.57m |
Equity | US$328.05m |
Total liabilities | US$19.20m |
Total assets | US$347.25m |
Recent financial health updates
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03Recent updates
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03Financial Position Analysis
Short Term Liabilities: MLYS's short term assets ($346.8M) exceed its short term liabilities ($19.2M).
Long Term Liabilities: MLYS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MLYS is debt free.
Reducing Debt: MLYS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MLYS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MLYS has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 61.7% each year.